John Kelly summarizes a recent paper published in JAMA that describes the benefits of robotic surgery versus open cystectomy.
Uromigos: Live and Unplugged, a first-ever, in-person event, will take place in Nashville from September 30 to October 1.
Bernard Escudier, MD, joins The Uromigos to talk about his career development and work in the field of kidney cancer.
Alex Wyatt joins The Uromigos to answer questions about ctDNA in prostate cancer and discuss his latest paper on that topic.
Declan Murphy and Matt Cooperberg debate the use of interventions in active surveillance for patients with prostate cancer.
Dr. Oliver Sartor, medical director of Tulane Cancer Center, discusses his career development and work in prostate cancer.
Kimryn Rathmell, MD, PhD, discusses highlights from the kidney cancer guidelines presented at the ASCO Annual Meeting.
Neal Shore describes his recent controversial paper and the over-treatment of patients with low-grade disease.
Phillip Kuo discusses phase 3 of the VISION trial that utilizes Lutetium-177 for the treatment of prostate cancer.
Veda Giri discusses germline variants among African American males and specific genes related to prostate cancer.
Data from the ENZAMET trial reconfirms survival benefit with enzalutamide in mHSPC, but the role of docetaxel is uncertain.
Matt Galsky discusses research posters presented that cover the effects of HER2-targeting ADCs for urothelial cancer.
Amir Goldkorn, MD, discusses findings from a phase 2 bladder trial, responses to neoadjuvant chemotherapy, and more.
Christopher W. Ryan, MD, shares long-awaited data about adjuvant everolimus in kidney cancer, the EVEREST trial, and results.
Jonathan Rosenberg gives an overview of the current landscape of antibody drug conjugates and their adverse effects.